Uncategorized

[Nature Communications] TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen’s safety and activity in patients with stable myeloproliferative neoplasms, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20%.

[Haematologica] 301 patients with a median age 60 years were enrolled. Of them, 287 and 274 patients collected ≥2 and ≥4×106 CD34+ cells/kg, respectively, with a median of 9.9×106 CD34+ cells/kg collected.

[EMBO Journal] The authors provide an in-depth review of the metabolic and epigenetic interplay regulating hematopoietic stem cell fate, and discuss the influence of metabolic stress stimuli, as well as alterations occurring during leukemic development.

[FierceBiotech] The data come from a Phase III clinical trial of pelabresib, a BET inhibitor that MorphoSys acquired in its $1.7 billion acquisition of Constellation Pharmaceuticals.

[Jama Oncology] The Phase II nonrandomized clinical trial enrolled 42 patients with uncommon EGFR mutations, of whom 40 were eligible.

[Biomedicine & Pharmacotherapy] Investigators observed that bleomycin induced enhanced mitophagy accompanied by increased mitochondrial ROS content in the murine alveolar epithelial cell line MLE12.

[European Respiratory Review] The authors look at the current evidence behind molecular monitoring in lung transplantation and ask if it is ready for routine clinical use.

[Journal of Translational Medicine] CCK8 assays, EdU assays, Scratch assay and Transwell migration assay were conducted to detect the role of circTENM3 in prostate cancer cells in vitro.

[Cell Reports] Investigators demonstrated that early postnatal growth of the pancreas unexpectedly involves massive acinar cell elimination.

[Heliyon] Researchers examined the CCCTC-binding factor (CTCF) function in pancreatic cancer (PC) and discovered that CTCF expression in PC tissues was significantly raised compared to neighboring healthy tissues.

[iScience] Unbiased transcriptome and metabolome analyses showed that PDAC cells with disrupted KRASG12D-NRF2 signalling (NRF2−/− cells) shift from aerobic glycolysis to metabolic pathways fed by amino acids.

[Cell Death & Disease] The authors found that high TACC3 expression in PDAC is associated with poor prognosis. shRNA-mediated TACC3 knockdown caused S phase arrest of the cell cycle and inhibited proliferation in PDAC cell lines.